AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12018633 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate levels
Number of subjects: 638
Study 12018633 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium levels
Number of subjects: 638
Study 12018633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca x P levels
Number of subjects: 638
Study 12018633 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase levels
Number of subjects: 638
Study 12018633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone (PTH) levels
Number of subjects: 638
Study 10050221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam 1.0 mg/h
Number of subjects: 20
Study 10050221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7720852 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based AIDS risk-reduction program
Number of subjects: 2392
Study 7720852 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 2392
Study 2041927 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin tablets (Abboticin 500 mg tablets)
Number of subjects: 86
Study 2041927 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid cream (Fucidin cream)
Number of subjects: 86
Study 2041927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 30973426 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to incivility
Number of subjects: 0
Study 30973426 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to incivility)
Number of subjects: 0
Study 30973426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 0
Study 31438925 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief mindfulness-based intervention (MBI), four sessions in total
Number of subjects: 154
Study 31438925 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 154
Study 31438925 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief mindfulness-based intervention (MBI)
Number of subjects: 154
Study 28077611 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Venous Catheter (UVC)
Number of subjects: 72
Study 28077611 — intervention group
Group type: COMPARATOR
Intervention: Peripherally Inserted Central Catheter (PICC)
Number of subjects: 72
Study 26260018 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser treatment (3 sessions every 4-6 weeks)
Number of subjects: 15
Study 26260018 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser treatment
Number of subjects: 15
Study 26260018 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated half of the scar)
Number of subjects: 15
Study 23739686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (CRYO) - 3 × 4 minutes at -30°C
Number of subjects: 24
Study 23739686 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 24
Study 23739686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (CRYO)
Number of subjects: 24
Study 21747289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration (OR) with D2O labeled fluid
Number of subjects: 10
Study 21747289 — intervention group
Group type: COMPARATOR
Intervention: Oral combined with intravenous rehydration (IVO) with D2O labeled fluid
Number of subjects: 10
Study 20011886 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 19
Study 20011886 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study 17550955 — intervention group
Group type: EXPERIMENTAL
Intervention: eMPC (enhanced model predictive control)
Number of subjects: 60
Study 17550955 — intervention group
Group type: COMPARATOR
Intervention: RMP (routine glucose management protocol)
Number of subjects: 60
Study 14989442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 5 ppm
Number of subjects: 70
Study 14989442 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iNO)
Number of subjects: 70
Study 11228294 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-Doubling Technology (FDT)
Number of subjects: 253
Study 11228294 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning Laser Polarimetry (GDx)
Number of subjects: 253
Study 11228294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Fiber Layer (NFL) photographs
Number of subjects: 253
Study 11228294 — intervention group
Group type: COMPARATOR
Intervention: Humphrey 24-2 test
Number of subjects: 253
Study 9758292 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 or 200 mg
Number of subjects: 1474
Study 9758292 — intervention group
Group type: COMPARATOR
Intervention: Comparator (500 or 1000 mg amoxicillin, or 625 mg amoxicillin/clavulanic acid)
Number of subjects: 1474
Study 7798463 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated exclusion criteria (borderline personality disorder, drug/alcohol dependence, and others)
Number of subjects: 0
Study 7798463 — intervention group
Group type: COMPARATOR
Intervention: Tricyclics
Number of subjects: 0
Study 2468049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg)
Number of subjects: 7
Study 2468049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29271486 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0
Study 29271486 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 0
Study 28817141 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) with butyl-cyanoacrylate (BC) adhesive (PRF group; n = 42)
Number of subjects: 125
Study 28817141 — intervention group
Group type: COMPARATOR
Intervention: BC adhesive alone (BC group; n = 42)
Number of subjects: 125
Study 28817141 — intervention group
Group type: COMPARATOR
Intervention: Sterile wet gauze compression (WG group; n = 41)
Number of subjects: 125
Study 26888806 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBNP administration (1.5 µg/kg bolus intravenous injection followed by 0.0075-0.03 µg·kg(‐1)·min(‐1) for up to 120 hours)
Number of subjects: 93
Study 26888806 — intervention group
Group type: COMPARATOR
Intervention: NIT treatment (10-100 µg/min intravenous infusion for 120 hours)
Number of subjects: 93
Study 23963331 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (135 µg/kg body weight intravenous over 72 hours)
Number of subjects: 328
Study 23963331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 23963331 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 328
Study 21406015 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoTwist needle
Number of subjects: 120
Study 18326136 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol and remifentanil (Group R)
Number of subjects: 40
Study 18326136 — intervention group
Group type: COMPARATOR
Intervention: Balanced inhalational anaesthesia with isoflurane (Group F)
Number of subjects: 40
Study 16612457 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (PP) for three-hour periods
Number of subjects: 41
Study 14667874 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 66
Study 14667874 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 66
Study 14667874 — intervention group
Group type: COMPARATOR
Intervention: Spontaneously conceived
Number of subjects: 66
Study 11712430 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 30
Study 11712430 — intervention group
Group type: COMPARATOR
Intervention: Control group (90 healthy people)
Number of subjects: 30
Study 8869763 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic dose of morphine
Number of subjects: 0
Study 8869763 — intervention group
Group type: COMPARATOR
Intervention: Low-dose morphine
Number of subjects: 0
Study 8869763 — intervention group
Group type: COMPARATOR
Intervention: Pupillometric study with morphine
Number of subjects: 0
Study 1290604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin bonding agents (8 different types)
Number of subjects: 135
Study 1290604 — intervention group
Group type: COMPARATOR
Intervention: Unfilled resin
Number of subjects: 135
Study 6427027 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate alone (50 mg/day, cycle days 5 to 9)
Number of subjects: 34
Study 6427027 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus human menopausal gonadotropin (2 ampules/day, cycle days 6, 8, and 10)
Number of subjects: 34
Study 6427027 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus human menopausal gonadotropin
Number of subjects: 34
Study 6427027 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate alone
Number of subjects: 34
Study 31132346 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete CHOICE
Number of subjects: 1008
Study 31132346 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care
Number of subjects: 1008
Study 30168626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 32
Study 30168626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 27194023 — intervention group
Group type: COMPARATOR
Intervention: QRS duration <120 ms
Number of subjects: 3754
Study 27194023 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration ≥120 ms
Number of subjects: 3754
Study 27194023 — intervention group
Group type: COMPARATOR
Intervention: Normal QRS morphology
Number of subjects: 3754
Study 27194023 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-LBBB QRS morphology
Number of subjects: 3754
Study 27194023 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBB QRS morphology
Number of subjects: 3754
Study 25283499 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine preemptive therapy
Number of subjects: 60
Study 25283499 — intervention group
Group type: COMPARATOR
Intervention: No antiviral therapy
Number of subjects: 60
Study 22404442 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-CT (lansoprazole 30 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week, followed by lansoprazole 30 mg b.i.d. + clarithromycin 500 mg b.i.d. + tetracycline 500 mg q.i.d. for 2nd week)
Number of subjects: 200
Study 22404442 — intervention group
Group type: COMPARATOR
Intervention: LA-CM (lansoprazole 30 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week, followed by lansoprazole 30 mg b.i.d. + clarithromycin 500 mg b.i.d. + metronidazole 500 mg t.i.d. for 2nd week)
Number of subjects: 200
Study 20569670 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with Aβ42
Number of subjects: 8
Study 20569670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 8
Study 20569670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated case
Number of subjects: 8
Study 18080055 — intervention group
Group type: COMPARATOR
Intervention: Delayed-release oral mesalamine 2.4 g/day (400 mg tablet)
Number of subjects: 301
Study 18080055 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release oral mesalamine 4.8 g/day (800 mg tablet)
Number of subjects: 301
Study 18080055 — intervention group
Group type: COMPARATOR
Intervention: Delayed-release oral mesalamine 2.4 g/day (400 mg tablet) in moderate disease subgroup
Number of subjects: 301
Study 18080055 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release oral mesalamine 4.8 g/day (800 mg tablet) in moderate disease subgroup
Number of subjects: 301
Study 15841784 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information provided in advance
Number of subjects: 169
Study 15841784 — intervention group
Group type: COMPARATOR
Intervention: No written information provided (control)
Number of subjects: 169
Study 11341495 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg)
Number of subjects: 27
Study 11341495 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 microg)
Number of subjects: 27
Study 11341495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9749223 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty (group 2: 1994-1995)
Number of subjects: 873
Study 9749223 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty (group 1: 1990-1991)
Number of subjects: 873
Study 7861799 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol intoxication
Number of subjects: 0
Study 7861799 — intervention group
Group type: COMPARATOR
Intervention: Sober condition
Number of subjects: 0
Study 7861799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain threshold
Number of subjects: 0
Study 7861799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of pain threshold to shock intensity and total aggression
Number of subjects: 0
Study 2518857 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg o.m.)
Number of subjects: 181
Study 2518857 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg b.d.)
Number of subjects: 181
Study 412995 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glucose, fructose and xylitol (1:2:1 ratio)
Number of subjects: 24
Study 412995 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 24
Study 31069922 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia in patients with dementia
Number of subjects: 0
Study 31069922 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of dementia after hypoglycemia
Number of subjects: 0
Study 27958765 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD/BC
Number of subjects: 52
Study 27958765 — intervention group
Group type: COMPARATOR
Intervention: EMD alone
Number of subjects: 52
Study 27089154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive enhancement therapy (n = 22)
Number of subjects: 31
Study 27089154 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 9)
Number of subjects: 31
Study 24151119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.2 mmol/kg)
Number of subjects: 15
Study 24151119 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.2 mmol/kg)
Number of subjects: 15
Study 22498181 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐counselling (≥ 8 messages)
Number of subjects: 387
Study 22498181 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (0 messages)
Number of subjects: 387
Study 19412196 — intervention group
Group type: EXPERIMENTAL
Intervention: biologic agents
Number of subjects: 0
Study 19412196 — intervention group
Group type: EXPERIMENTAL
Intervention: new DMARDs
Number of subjects: 0
Study 17898955 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs combined with acupuncture (CH‐A)
Number of subjects: 61
Study 17898955 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (oral intake of vitamin C and E, external application of quban powder)
Number of subjects: 61
Study 15259826 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus CBT
Number of subjects: 90
Study 15259826 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 90
Study 12018882 — intervention group
Group type: EXPERIMENTAL
Intervention: Awakened by AMI symptoms
Number of subjects: 3309
Study 12018882 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 3309
Study 12018882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ejection fraction
Number of subjects: 3309
Study 10463555 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention consisting of a review of the child's medical record, explanation of future well-child visits, discussion of the role of the PCP, and a follow-up appointment prior to discharge from the PED.
Number of subjects: 195
Study 10463555 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 195
Study 10463555 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 195
Study 7756226 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with 2.7 g of MaxEpa daily (1.62 g of eicosapentaenoic acid and 1.08 g of docosahexaenoic acid)
Number of subjects: 233
Study 2156885 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide alone for 5-6 months
Number of subjects: 19
Study 2156885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg daily)
Number of subjects: 19
Study 2156885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6996793 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg
Number of subjects: 99
Study 6996793 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg
Number of subjects: 99
Study 6996793 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg
Number of subjects: 99
Study 30661093 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Number of subjects: 51
Study 30661093 — intervention group
Group type: COMPARATOR
Intervention: Control (no endometrial injury)
Number of subjects: 51
Study 28390649 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound Clamp (WC)
Number of subjects: 10
Study 28390649 — intervention group
Group type: COMPARATOR
Intervention: Skin Suture (SS)
Number of subjects: 10
Study 25762759 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized motivational feedback at baseline, 3 months, and 6 months; 12 weeks of cessation counseling and nicotine patches
Number of subjects: 60
Study 25762759 — intervention group
Group type: COMPARATOR
Intervention: Usual care (self‐help guide and brief cessation advice)
Number of subjects: 60
Study 24029622 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM) group earning one draw per call from a prize bowl
Number of subjects: 0
Study 24029622 — intervention group
Group type: COMPARATOR
Intervention: Fixed dollar CM group earning $1 for each call
Number of subjects: 0
Study 24029622 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received abstinence rewards according to a high-value voucher incentive schedule confirmed by urine testing
Number of subjects: 0
Study 22463614 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of red blood cells
Number of subjects: 237
Study 22463614 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 237
Study 22463614 — intervention group
Group type: EXPERIMENTAL
Intervention: sPLA2 threshold level ≥ 48 ng/ml
Number of subjects: 237
Study 20817936 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone
Number of subjects: 1090
Study 20817936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision plus exercise
Number of subjects: 1090
Study 20817936 — intervention group
Group type: COMPARATOR
Intervention: Multi-component interventions (exercise, vision, home hazard reduction)
Number of subjects: 1090
Study 17197464 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 degrees angle, forward camber
Number of subjects: 200
Study 17197464 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 degrees angle, reverse camber
Number of subjects: 200
Study 17197464 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 degrees angle, forward camber
Number of subjects: 200
Study 17197464 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 degrees angle, reverse camber
Number of subjects: 200
Study 16192584 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT)
Number of subjects: 348
Study 16192584 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 348
Study 11984215 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (A) 20 mg/day
Number of subjects: 675
Study 11984215 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (P) 20 mg/day + Gemfibrozil (G) 1200 mg/day
Number of subjects: 675
Study 11984215 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (S) 20 mg/day + Gemfibrozil (G) 1200 mg/day
Number of subjects: 675
Study 11984215 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (P) 20 mg/day + Ciprofibrate (C) 100 mg/day
Number of subjects: 675
Study 11984215 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (S) 20 mg/day + Ciprofibrate (C) 100 mg/day
Number of subjects: 675
Study 9534678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic enhancement
Number of subjects: 0
Study 9534678 — intervention group
Group type: COMPARATOR
Intervention: Test card procedure
Number of subjects: 0
Study 7616842 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber meals (HF)
Number of subjects: 10
Study 7616842 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber meals (LF)
Number of subjects: 10
Study 2375883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1500 mg d‐1)
Number of subjects: 0
Study 2375883 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 497093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release oral procainamide preparation 1
Number of subjects: 10
Study 497093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release oral procainamide preparation 2
Number of subjects: 10
Study 30910320 — intervention group
Group type: EXPERIMENTAL
Intervention: β blockers (propranolol up to 160 mg twice a day or carvedilol ≤25 mg/day)
Number of subjects: 201
Study 30910320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 30910320 — intervention group
Group type: EXPERIMENTAL
Intervention: β blockers
Number of subjects: 201
Study 29135115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3mg/kg, administered with short 30-min i.v. infusion every 3 weeks, total of 4 doses
Number of subjects: 89
Study 26320827 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 300mg daily
Number of subjects: 94
Study 26320827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 23384300 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.05 mg·kg(‐1) ·min(‐1) after tracheal intubation, 0.3 mg·kg(‐1) ·min(‐1) during CPB, 0.03‐0.05 mg·kg(‐1) ·min(‐1) until the end of surgery)
Number of subjects: 30
Study 23384300 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30
Study 23384300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 30